Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

57 estudios en Digestive Diseases
(solo estudios abiertos).

Filtra esta lista de estudios por sede, estado, etc.

1. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

   Rochester, Minn.

   The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

2. Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study)

   Jacksonville, Fla.

   The purpose of this study is to collect PillCamTM SB3 capsule endoscopy (CE) procedures and subsequent device-assisted enteroscopy (DAE) procedures data (double balloon enteroscopy (DBE), single balloon enteroscopy (SBE) and spiral enteroscopy (SE)) in medical centers in the United States (US).

3. Study Of Gastric Cancer And Limited Peritoneal Metastasis Using Robotic Cytoreduction And Hyperthermic Intraperitoneal Chemotherapy

   Rochester, Minn.

   The purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with gastric adenocarcinoma with limited low volume peritoneal metastasis and/or positive peritoneal cytology undergoing robotic cytoreduction and hyperthermic intraperitoneal chemotherapy.

4. Study To Evaluate Efficacy, Safety And Tolerability Of HM15211 In Subjects

   Rochester, Minn.

   The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on the liver by proportion of subjects who achieve resolution of steatohepatitis on overall histopathological reading and no worsening of liver fibrosis on NASH Clinical Research Network (CRN) fibrosis score.

   Resolution of NASH is defined as non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of 0–1 for inflammation, 0 for ballooning, and any other value for steatosis

5. Study to Better Understand the Development of Irritable Bowel Disease (IBD) and Related Diseases as a Step Toward Improving Disease Outcomes.

   Rochester, Minn.

   The purpose of this study is to better understand disease development of Irritiable Bowel Disease (IBD) and related diseases as a step to improving disease outcomes.

6. Transforming Healthcare and Outcomes for Children with Inflammatory Bowel Disease

   La Crosse, Wis., Mankato, Minn., Rochester, Minn., Eau Claire, Wis.

   The purpose is to put the information into a very large database, which can then be used to improve patient care and achieve the best health outcomes possible for children with IBD.

7. A Study To Validate DNA Methylation Markers For Universal And Site-specific Guided Cancer Detection

   Rochester, Minn.

   The purpose of this study is to validate candidate universal and site-specific methylated DNA markers (MDMs) in DNA extracted from formalin-fixed paraffin embedded primary tumor and control specimens.

8. A Study to Evaluate the Effectiveness of a Healthy Living Weight Loss Program in Obese Patients Undergoing Bariatric Endoscopy on Weight Loss Outcomes

   Rochester, Minn.

   The purpose of this study is to compare weight loss, improvement of comorbidities, improvement of lipid profile, blood sugar in patients undergoing endoscopic sleeve gastroplasty or intragastric balloon between patients who are in a weight loss program and those who are not.

9. A Study to Better Understand Why Patients Gain Weight After Undergoing Liver Transplantation

   Rochester, Minn.

   The purpose of this study is to understanding the mechanisms of weight gain in patients following liver transplantation, action, and indicate approaches to prevent weight gain.

10. Early Pancreatic Cancer Detection

    Jacksonville, Fla.

    The primary purpose of this study is to standardize the collection of demographic, clinical, and imaging data, and biosamples for a large high-risk familial Pancreatic Ductal Adenocarinoma (PDAC) cohort at consortium clinical cancer centers, worldwide.